Compared with a combination treatment of LABA/LAMA, ICS/LABA/LAMA combination therapy was associated with a significantly greater pooled risk reduction in COPD exacerbation.
Few individuals hospitalized for COPD receive pulmonary rehabilitation.
Three-dimensional "super clusters" in patients with COPD could play a role in the progression of COPD to emphysema.
There may an increased risk for tuberculosis in patients with COPD within 3 years of inhaled corticosteroid use.
The FDA has approved Yupelri inhalation solution for the maintenance treatment of patients with COPD.
The overall rate of asthma-COPD overlap was 3.8%, with a maximum prevalence of 7.8% in Matlab, Bangladesh.
Adults with COPD treated with both inhaled corticosteroids and low-dose theophylline as adjunct therapy did not have fewer exacerbations compared with patients treated with inhaled corticosteroids only.
Half of patients with COPD report use of inhaler medications that are not in alignment with the current treatment recommendations.
Air-driven bronchodilator nebulization is preferable to oxygen-driven nebulization in patients experiencing acute COPD exacerbations.
The increased occurrence of periprocedural complications in patients with COPD was largely attributed to cardiac arrest, myocardial infarctions, and no-reflows.
Albuminuria was associated with greater lung function decline in patients with chronic obstructive pulmonary disease.
Cystic fibrosis transmembrane conductance regulator dysfunction is associated with worsened airway disease in patients with COPD.
No difference in mortality, but there may be an elevated risk for suicide with long-term benzodiazepine use in patients with COPD and comorbid PTSD.
Middle-aged testosterone replacement therapy users with COPD had a greater reduction in hospitalizations compared with nonusers.
The risk for obstructive lung disease was nearly 8 times greater in heavy stable smokers compared with never-smokers.
Early pulmonary rehabilitation after hospitalization for an acute exacerbation of COPD was an effective intervention for reducing mortality.
The FDA has approved updated labeling for Stiolto Respimat to include COPD exacerbation data and a revised indication.
Patients who received a discharge care bundle after being hospitalized for an acute exacerbation of COPD had a lower rate of readmission.
Patients with chronic obstructive pulmonary disease who used opioids were more likely to be intubated during their hospitalization compared with nonopioid users
No changes were observed in 12-lead electrocardiographic recordings associated with daily doses of revefenacin 88 μg and 175 μg in patients with COPD.
Regardless of reversibility status, patients with COPD experienced significant improvements with triple vs dual therapy.
There was a trend toward a reduction in mortality in patients with COPD who received beta-blocker treatment compared with patients who did not.
Disrupting regular combination inhaled corticosteroid therapy refills increased hospitalizations and exacerbations.
Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.
Alcohol abuse, fluid and electrolyte abnormalities, and pulmonary circulation disorders increased the risk for noninvasive ventilation in a COPD exacerbation.
The most common error related to the use of metered dose inhalers was the failure to attach the inhaler to a spacer.
Patients with severe COPD improved significantly in both endurance time and walking distance with the use of automatically titrated oxygen flow vs constant oxygen flow.
Treatment with prophylactic antibiotics was associated with a reduction in the frequency of COPD exacerbations and improved quality of life.
Sleep disturbances caused by the symptoms of COPD are associated with airway constriction heterogeneity, which could be reflective of peripheral airway dysfunction.
No meaningful associations were detected in procedural listing preferences and survival outcomes in patients with COPD or interstitial lung disease awaiting lung transplant.
Clinicians are eager for new therapies to address the damage to airways and lung parenchyma because no current therapy can completely reverse COPD damage.
After 12 months, patients in the Urban Training™ group had increased their number of daily steps by 816 compared with 64 steps in the usual care group.
Additional bronchodilation and hyperinflation reduction occurred in COPD when RPL554, an inhaled PDE 3 and 4 inhibitor, was combined with standard bronchodilators.
Changing pollination patterns, extreme weather events, rising sea levels, air pollution, and extreme temperatures all negatively affect respiratory conditions.
There were no statistically significant differences in mortality rates, rates of COPD exacerbations, lung inflammation, or serious adverse events between a once-daily combined inhaled corticosteroid/LABA and LAMA.
A total of 35% of heroin smokers screened positive for COPD.
Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.
No difference in exacerbations with indacaterol/glycopyrronium for non-frequently exacerbating COPD.
First bronchoscopic lung volume reduction using endobronchial valve performed at Temple University in Philadelphia, PA.
In their Complete Response Letter, the FDA stated that they require more clinical data to support approval.
Cardiovascular risk within 30 days of therapy start was approximately 2-fold higher with the incident use of tiotropium in COPD.
In patients with emphysema, deposition fraction was significantly lower than in other individuals, but no significant differences were found between healthy never smokers and current or former smokers.
Thigh muscle volume showed significant improvements in patients with COPD who were treated with bimagrumab vs placebo.
Patients with COPD who have comorbidities are less likely to receive beneficial treatment for exacerbations.
The incidence of undiagnosed COPD was 26%, and based on the GOLD spirometry grading system, 95% had mild to moderate disease.
After 2.1 years of follow-up, 49% of patients who had emphysema on chest CT were readmitted for heart failure and 24% had died.
Although the summer season yielded the lowest overall COPD exacerbation rate, 43% of exacerbations during summer were moderate to very severe.
The average annual prevalence of bronchiectasis from 2012 to 2014 was 701 cases per 100,000 individuals.
S pneumoniae colonization was positively associated with H influenza colonization, whereas negative associations were reported between P aeruginosa and H influenzae and between P aeruginosa and M catarrhalis.
Comorbid chronic rhinitis is significantly associated with 30-day hospital readmissions related to asthma and chronic obstructive pulmonary disease.
Prior use of systemic corticosteroids and prior isolation of Pseudomonas aeruginosa were risk factors associated with the presence of Pseudomonas aeruginosa in COPD.
Through Bluetooth technology, clinicians and patients will be able to share and monitor inhaler usage.
Short-term corticosteroids may be sufficient for treating patients with acute COPD exacerbations.
Patients with COPD who had a relative lymphocyte count ≤20% had a higher risk for mortality.
When compared with a placebo control cannabis, cannabis had no effect on breathlessness intensity ratings during exercise at isotime or on exercise endurance time.
Socioeconomic and lifestyle risk factors had a more significant role in the development of COPD and asthma overlap syndrome in women than air pollution.
Shorter telomere length was associated with worse health status in chronic obstructive pulmonary disease, as measured by St. George's Respiratory Questionnaire.
Anxiety symptoms are more common in patients with COPD as determined by the Generalized Anxiety Disorder, Hospital Anxiety and Depression scale, and Anxiety Inventory for Respiratory Disease screening questionnaires vs the DSM-V criteria.
Although emerging data offer valuable clues, the pathophysiological distinctions between different phenotypes of chronic obstructive pulmonary disease are still poorly understood.
Mortality was significantly increased among patients with rheumatoid arthritis and COPD.
Inhaling and smoking heroin and cocaine increase the risk for asthma exacerbations and decreased pulmonary function; marijuana is associated with wheezing, cough, and sputum production.
Patients who were hospitalized for non-severe acute exacerbations of COPD did not experience improved outcomes when antibiotics were administered for longer than 24 hours.
NT-proBNP may be an independent predictor of respiratory exacerbations in patients with COPD even without overt cardiovascular disease.
Collagen biomarkers were significantly higher at extreme exacerbations, and were also associated with circulating adrenomedullin.
Rates of pulmonary embolism ranged from 3.3% to 29.1% in patients with a clinical diagnosis of an acute exacerbation of COPD.
There were differences in use of steroids and antibiotics noted between teaching and non-teaching hospital staff.
Whole-genome sequencing was valuable in identifying a large number of potentially significant functional variants in severe COPD.
Although COPD has been identified as a risk factor for cardiovascular disease, researchers are less certain about the relationship between COPD and stroke.
Frequent asthma, bronchitis, allergy demonstrated the strongest association with , lower FEV1, lower FEV1/forced vital capacity, and increased risk for COPD.
Dexamethasone was not effective in reducing the incidence of acute mountain sickness and altitude-related adverse health effects in individuals with mild to moderate COPD.
Regardless of renal impairment, combination therapy with tiotropium/olodaterol was safe and tolerable in patients with moderate to very severe COPD.
Study authors performed a post hoc pooled analysis of data from 10 trials to assess the safety and efficacy of umeclidinium/vilanterol in elderly symptomatic patients with COPD.
Gastroesophageal reflux disease is associated with an increase in bronchitis symptoms in patients with COPD.
Increase in all-cause, cardiovascular disease, cancer, diabetes, kidney disease, suicide, and COPD mortality.
The approval was based on results from a multicenter study (LIBERATE) of 190 patients with severe emphysema.
For patients with advanced COPD, the use of formal palliative care services and long-term oxygen therapy has increased but remains low.
The clinical significance of emphysema was greater in people living with HIV vs those without HIV.
The use of formal palliative care services among patients with chronic obstructive pulmonary disease increased by 1% per year, going from 5.3% in 2004 to 14.3% in 2014.
A 72-year-old man with a 50 pack-year smoking history and multiple comorbidities, including COPD, presents to the emergency department with left-sided hemiparesis and sensory loss.
There was as significant change in Bristol COPD Knowledge Questionnaire scores in patients who received a brief education program at the time of an acute exacerbation of COPD.
Acute COPD exacerbations were associated with an increased risk for myocardial infarction and ischemic stroke.
Zephyr® Endobronchial Valve EBV® treatment improved FEV1 in patients with heterogeneous emphysema.
The inclusion of residual volume-to-total lung capacity ratio may add another dimension to COPD not routinely captured by standard airflow indices that could be predictive of lower maximum exercise capacity.
A direct de-escalation from triple therapy to indacaterol/glycopyrronium may be appropriate in patients with infrequent COPD exacerbations.
A definition of a pulmonary vascular phenotype of chronic obstructive pulmonary disease has been proposed.
Recent research suggests that increasing obesity class is independently associated with worse respiratory-specific and general quality of life outcomes in COPD.
Tiotropium may be more effective in reducing the rate of moderate and severe chronic obstructive pulmonary disorder exacerbations when used in combination with olodaterol vs tiotropium alone.
Patients with COPD had a nearly 2-fold increased risk for developing atrial fibrillation compared with patients without COPD.
Using e-cigarettes every day or some days increased the likelihood of developing chronic obstructive pulmonary disease.
In this study, researchers examined the appropriateness of diagnosis and treatment of chronic obstructive pulmonary disease in individuals with and without HIV.
Steroid dosing and glucose levels were not associated with an increase in hospital readmissions related to COPD exacerbations.
No association was found between the degree of lung function impairment and the development of mild cognitive impairment in chronic obstructive pulmonary disease.
The pooled safety analysis included data from the TRILOGY, TRINITY, and TRIBUTE studies.
Incident diuretic use was associated with increased rates of respiratory-related morbidity and mortality in older adults with chronic obstructive pulmonary disease.
Combination therapy with LABA and LAMA yielded a lower annualized rate of COPD exacerbations compared with triple therapy.
PHQ-9 and PHQ-2 show factorial validity, invariance, and reliability for measuring depression in patients with chronic obstructive pulmonary disease.
Emerging guidelines for diagnosing and treating asthma COPD overlap syndrome will help clinicians better manage patients and prevent serious adverse effects.
Palliative care consultation was linked to a reduction in hospital costs for hospitalized adults with serious illness, such as COPD.
Survival at 6 months was significantly associated with acute respiratory failure and history of COPD.
A higher proportion of patients with COPD and a blood eosinophil count of ≥0.34×109/L had elevated markers of low-grade systemic inflammation regardless of forced expiratory volume in 1 second.